Michael E. Menefee

1.8k total citations
45 papers, 1.3k citations indexed

About

Michael E. Menefee is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Michael E. Menefee has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Cancer Research. Recurrent topics in Michael E. Menefee's work include Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Cancer Treatment and Pharmacology (8 papers). Michael E. Menefee is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Cancer Treatment and Pharmacology (8 papers). Michael E. Menefee collaborates with scholars based in United States, Singapore and Canada. Michael E. Menefee's co-authors include Tito Fojo, Antonio Tito Fojo, Keith C. Bible, Robert C. Smallridge, Charles Erlichman, Jill K. Burton, William J. Maples, Vera J. Suman, Julian R. Molina and Anne M. Traynor and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Lancet Oncology.

In The Last Decade

Michael E. Menefee

42 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael E. Menefee United States	15	610	560	484	209	181	45	1.3k
Alexandra Eyzaguirre United States	8	564 0.9×	255 0.5×	722 1.5×	244 1.2×	263 1.5×	13	1.1k
Masaki Kitazono Japan	22	659 1.1×	114 0.2×	697 1.4×	154 0.7×	233 1.3×	48	1.3k
Douglas E. Linn United States	11	334 0.5×	249 0.4×	847 1.8×	953 4.6×	379 2.1×	17	1.5k
Carlos García-Echeverría Switzerland	6	393 0.6×	164 0.3×	1.2k 2.4×	291 1.4×	255 1.4×	9	1.5k
Susan Korenchuk United States	13	348 0.6×	93 0.2×	896 1.9×	462 2.2×	204 1.1×	18	1.4k
Silvia Rita Vitale Italy	16	251 0.4×	112 0.2×	429 0.9×	182 0.9×	333 1.8×	46	978
Graham H.P. Richmond United Kingdom	5	473 0.8×	108 0.2×	492 1.0×	321 1.5×	175 1.0×	6	947
María G. Kuba United States	14	773 1.3×	69 0.1×	897 1.9×	445 2.1×	370 2.0×	20	1.5k
S. Vignati Italy	15	793 1.3×	105 0.2×	879 1.8×	569 2.7×	388 2.1×	22	1.6k
Bradley Wubbenhorst United States	14	281 0.5×	81 0.1×	449 0.9×	173 0.8×	311 1.7×	28	1.0k

Countries citing papers authored by Michael E. Menefee

Since Specialization

Citations

This map shows the geographic impact of Michael E. Menefee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Menefee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Menefee more than expected).

Fields of papers citing papers by Michael E. Menefee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Menefee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Menefee. The network helps show where Michael E. Menefee may publish in the future.

Co-authorship network of co-authors of Michael E. Menefee

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Menefee. A scholar is included among the top collaborators of Michael E. Menefee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Menefee. Michael E. Menefee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davidson, Ana D., et al.. (2025). Potential Landscapes for Conservation of the Black‐Tailed Prairie Dog Ecosystem. Diversity and Distributions. 31(1). 1 indexed citations

Davidson, Ana D., et al.. (2023). Present and future suitable habitat for the black-tailed prairie dog ecosystem. Biological Conservation. 286. 110241–110241. 2 indexed citations

Hubbard, Joleen M., Jun Yin, Erin L. Schenk, et al.. (2021). Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Investigational New Drugs. 40(1). 115–123. 2 indexed citations

Iñiguez‐Ariza, Nicole M., Sina Jasim, Mabel Ryder, et al.. (2020). Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. The Journal of Clinical Endocrinology & Metabolism. 105(7). e2346–e2357. 13 indexed citations

Xie, Hao, Jun Yin, Manisha H. Shah, et al.. (2019). A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Investigational New Drugs. 37(4). 755–762. 19 indexed citations

Menefee, Michael E., Yutao Gong, Pallavi S. Mishra‐Kalyani, et al.. (2019). Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.. Journal of Clinical Oncology. 37(15_suppl). 9105–9105. 4 indexed citations

Miller, Daniel, Stephen Ko, Mark R. Waddle, et al.. (2017). High Risk Oral Cavity Carcinoma Patient Outcomes Following Minimally Invasive Surgery and Adjuvant Radiation. International Journal of Radiation Oncology*Biology*Physics. 99(2). E359–E360.

Konda, Bhavana, Michael V. Knopp, Peter R. Martin, et al.. (2017). Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC).. Journal of Clinical Oncology. 35(15_suppl). e17580–e17580. 2 indexed citations

Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2014). Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(18). 4747–4757. 55 indexed citations

10.

Smallridge, Robert C., John A. Copland, Marcia S. Brose, et al.. (2013). Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. The Journal of Clinical Endocrinology & Metabolism. 98(6). 2392–2400. 93 indexed citations

11.

Schenk, Erin L., Andrea E. Wahner Hendrickson, Donald W. Northfelt, et al.. (2013). Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Investigational New Drugs. 31(5). 1251–1256. 14 indexed citations

12.

Cooper, Simon, Christina A. Von Roemeling, Laura A. Marlow, et al.. (2012). Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers. Molecular Cancer Therapeutics. 11(10). 2105–2115. 52 indexed citations

13.

Bible, Keith C., Vera J. Suman, Michael E. Menefee, et al.. (2012). A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 97(9). 3179–3184. 131 indexed citations

14.

Menefee, Michael E., Robert C. Smallridge, & Keith C. Bible. (2012). Systemic Therapeutic Approaches to Advanced Thyroid Cancers. American Society of Clinical Oncology Educational Book. 389–392. 2 indexed citations

15.

Haluska, Paul, Jinzhou Huang, Bernard Lam, et al.. (2011). MEDI-573 as a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase I PK/PD, safety data, and disease linkage studies in breast cancer.. Journal of Clinical Oncology. 29(27_suppl). 271–271. 5 indexed citations

16.

Bible, Keith C., Vera J. Suman, Julian R. Molina, et al.. (2010). Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. The Lancet Oncology. 11(10). 962–972. 330 indexed citations

17.

Huang, Hui, Michael E. Menefee, Maureen Edgerly, et al.. (2010). A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 16(5). 1634–1641. 34 indexed citations

18.

Stein, Wilfred D., Hui Huang, Michael E. Menefee, et al.. (2009). Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma. The Cancer Journal. 15(5). 441–447. 31 indexed citations

19.

Fojo, Tito & Michael E. Menefee. (2007). Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology. 18. v3–v8. 186 indexed citations

20.

Fojo, Antonio Tito & Michael E. Menefee. (2005). Microtubule Targeting Agents: Basic Mechanisms of Multidrug Resistance (MDR). Seminars in Oncology. 32(6 Suppl 7). 3–8. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact